Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease

Bone Marrow Transplantation

Volumn 27, Issue 11, 2001, Pages 1133-1140

  Kumar, S ^a   Chen, M G ^a   Gastineau, D A ^a   Gertz, M A ^a   Inwards, D J ^a   Lacy, M Q ^a   Tefferi, A ^a   Harmsen, W S ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic bone marrow transplantation; CYA; Cytomegalovirus; MTX; Prednisone; Survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; PREDNISONE;

ACUTE DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CHRONIC DISEASE; CHRONIC LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; INCIDENCE; INFANT; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHORT COURSE THERAPY; STATISTICS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHOTREXATE; MIDDLE AGED; ODDS RATIO; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034961465     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703053     Document Type: Article

References (48)

1. Bone marrow transplantation
2. Risk factors for acute graft-versus-host disease
3. An analysis of factors predisposing to chronic graft-versus-host disease
4. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
5. T-cell depletion of HLA-identical transplants in leukemia
6. Bone marrow transplantation in acute leukemia - Remaining problems
7. Allogeneic marrow grafts in man using cyclophosphamide
8. Marrow transplantation for leukemia and aplastic anemia: Two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease
9. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
10. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy
11. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia
12. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
13. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
14. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
15. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow malignancy
16. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: Comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone
17. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: A prospect randomized study
18. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention
19. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease
20. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease
21. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
22. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: Effect on chronic graft-vs.-host disease and long-term survival
23. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide
24. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
25. Bone-marrow transplantation
26. Regression models and life-tables
27. Nonparametric estimation from incomplete observations
28. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation
29. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
30. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
31. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis
32. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia
33. T cell tolerance after bone marrow transplantation in mice
34. Self recognition in allogeneic radiation bone marrow chimeras. A radiation-resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells
35. Achieving alloengraftment without graft-versus-host disease: Approaches using mixed allogeneic bone marrow transplantation
36. Antigen localization and migration in immunity and tolerance
37. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
38. Cytomegalovirus expression in minor salivary glands and chronic graft-versus-host disease
39. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation
40. Cytomegalovirus infection after marrow transplantation for aplastic anemia
41. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease
42. Cytomegalovirus infection in leucocytes after bone marrow transplantation demonstrated by mRNA in situ hybridization
43. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogenic marrow recipients with leukemia
44. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients
45. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study
46. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
47. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD
48. Allogenic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts